{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T22:44:26Z","timestamp":1785278666945,"version":"3.55.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.mayocp.2022.11.018","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T06:34:18Z","timestamp":1675233258000},"page":"351-352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["In Reply: ACEI and ARB \u2014 Each Unique RAAS Inhibitors"],"prefix":"10.1016","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6707-1629","authenticated-orcid":false,"given":"Kamal","family":"Awad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl J.","family":"Lavie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.mayocp.2022.11.018_bib1","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1093\/eurheartj\/ehs075","article-title":"Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients","volume":"33","author":"van Vark","year":"2012","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.mayocp.2022.11.018_bib2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacc.2012.10.011","article-title":"A\u00a0meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure","volume":"61","author":"Savarese","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.mayocp.2022.11.018_bib3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.mayocp.2015.10.019","article-title":"Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254,301 patients from randomized trials","volume":"91","author":"Bangalore","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"10.1016\/j.mayocp.2022.11.018_bib4","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.mayocp.2022.06.036","article-title":"Effect of the renin-angiotensin system inhibitors on inflammatory markers: a systematic review and meta-analysis of randomized controlled trials","volume":"97","author":"Awad","year":"2022","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"10.1016\/j.mayocp.2022.11.018_bib5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/ajh\/hpab108","article-title":"Renin angiotensin blockers and cardiac protection: from basis to clinical trials","volume":"35","author":"L\u00e9vy","year":"2022","journal-title":"Am J Hypertens"},{"issue":"10","key":"10.1016\/j.mayocp.2022.11.018_bib6","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1056\/NEJMoa1008816","article-title":"Irbesartan in patients with atrial fibrillation","volume":"364","author":"Yusuf","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.mayocp.2022.11.018_bib7","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1056\/NEJMoa0805710","article-title":"Valsartan for prevention of recurrent atrial fibrillation","volume":"360","author":"Disertori","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.mayocp.2022.11.018_bib8","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.2337\/diacare.23.12.1823","article-title":"Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial","volume":"23","author":"O\u2019Hare","year":"2000","journal-title":"Diabetes Care"},{"issue":"9386","key":"10.1016\/j.mayocp.2022.11.018_bib9","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet"},{"issue":"7339","key":"10.1016\/j.mayocp.2022.11.018_bib10","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/bmj.324.7339.699","article-title":"Use of ramipril in preventing stroke: double blind randomised trial","volume":"324","author":"Bosch","year":"2002","journal-title":"BMJ"},{"issue":"16","key":"10.1016\/j.mayocp.2022.11.018_bib11","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1001121","article-title":"Effect of valsartan on the incidence of diabetes and cardiovascular events","volume":"362","author":"McMurray","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.mayocp.2022.11.018_bib12","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s00125-011-2325-z","article-title":"Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study","volume":"54","author":"Imai","year":"2011","journal-title":"Diabetologia"},{"issue":"12","key":"10.1016\/j.mayocp.2022.11.018_bib13","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1056\/NEJMoa0804593","article-title":"Telmisartan to prevent recurrent stroke and cardiovascular events","volume":"359","author":"Yusuf","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mayocp.2022.11.018_bib14","article-title":"Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension","volume":"8","author":"Li","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"15","key":"10.1016\/j.mayocp.2022.11.018_bib15","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N\u00a0Engl J Med"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619622006681?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619622006681?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:39:51Z","timestamp":1758418791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619622006681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0025619622006681"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2022.11.018","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In Reply: ACEI and ARB \u2014 Each Unique RAAS Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2022.11.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2022.11.017","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}